The company expects insulin, its other branded formulations and research services to drive growth.
Bureaucratic delays are stifling growth in the sector. India should be far more aggressive in launching 'look alike' biological molecules in a fast track manner.
In an interview with Nandita Datta she talks about biotechnology becoming the new buzzword and what it takes to build a successful career.
Mazumdar-Shaw left open whether Biocon will go in for a higher stake or will completely take over the company, which is located near Frankfurt and specialises in manufacturing and marketing a unique range of its own patent-free medicines as well as low-cost drugs from Europan Union nations.
As many as six women, including O P Jindal group chairperson Savitri Jindal and Biocon's Kiran Mazumdar Shaw, have made it to the Forbes' list of 100 richest Indians this year.
How the business world celebrated Christmas!
Amateur filmmaker Anubhav Srivastava on how his unique film project changed his life.
New Zealand Prime Minister Helen Clarke on Monday said there were immense opportunities to enhance bilateral trade with India.
A quiz on women who have made it big in the corporate world.
On course to become India's first biotech company to be listed on a stock exchange, Bangalore-based Biocon Ltd on Thursday kicked off a roadshow for its initial public offering that opens on March 11.
Leading biotech firm, Biocon Ltd, on Tuesday said it would invest $10 million (about Rs 45 crore) in the next 12 months to expand its facilities.
Three Indian women -- ICICI Bank deputy managing director Chanda Kochhar, HSBC India CEO Naina Lal Kidwai and Biocon head Kiran Mazumdar-Shaw -- have been named among the world's 50 most powerful businesswomen by the Fortune magazine.
Biotechnology major Biocon India Ltd plans to invest over Rs 500 crore on its expansion plans over the next two years.
Indian biotech firm Biocon is developing potential 'blockbuster' drugs for treatment of cancer and diabetes, which could hit the market in two to four years.
Infosys will comply with whatever regulations and guidelines Karnataka comes up with, a top company official said on Thursday on the proposed reservations for locals in private firms in the state. Infosys employs over 3.15 lakh people at present across the globe. "We are planning to work with all the regulations of the state and central governments.
Addressing aspiring entrepreneurs, Biocon Chief Shaw adviced them never to fear failure.
Biotech major Biocon will file an application with the US Federal Drug Administration to begin clinical trials for oral insulin, which, it says, would be the world's first insulin that could be consumed orally.
India's largest biotech firm Biocon on Wednesday launched its "recombinant human insulin (r-DNA), Insugen
"We are growing fast. We are planning to double the manpower to 4,000 from 2,000 at present. Within a very short period we increased the number of employees by 500 to reach 2000," Biocon Chairman and Managing Director Kiran Mazumdar Shaw said.
Biotech major Biocon, which has projected sales turnover of Rs 700-750 crore (Rs 7-7.5 billion) this year, on Friday said it will launch recombinant human insulin in two weeks.
Biotech firm Biocon India on Friday reported net profits of Rs 138.63 crore (Rs 1.39 billion) for the year 2003-04, a growth of 219 per cent over Rs 43.51 crore (Rs 435.1 million) recorded for the previous fiscal.
Biocon on Thursday reported a 12 per cent decline in consolidated net profit to Rs 174 crore (Rs 1.74 billion) for the year ended March 31, 2006 from Rs 198 crore (Rs 1.98 billion) in FY05.\n
The government will investigate every Indian name appearing in an unprecedented leak of financial records, known as the 'Pandora Papers', which alleged that many world leaders have secret offshore stores of wealth.
Arundhati Bhattacharya, the chairperson of country's largest bank SBI, has been named as the most-powerful woman in business in India by Fortune magazine.
Infy to cast wide net in CEO search, may go back to 'alumni'
'It is not just the US and European opportunity, but it is a huge global opportunity.'
The company has received approval from the Drugs Controller General of India (DCGI) to market Itolizumab injection 25mg/5mL solution for emergency use in India for the treatment of cytokine release syndrome in moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19.
Submits new settlement offer to SBI
Yet another achievement is added to PeeCee's growing list.
The Karnataka government on Wednesday put the reservation bill for Kannadigas in private firms on hold amid fierce criticism from business leaders and tech tycoons.
Earlier, Jaslok Hospital had issued an advisory to its doctors to avoid prescribing drugs manufactured by Ranbaxy.
Sebi has barred Allegro Capital and one of its senior executives from the securities market for one year in a case related to alleged insider trading activities in the shares of Biocon. Besides, the market watchdog has directed them to disgorge wrongful gains along with interest. The amount would be more than Rs 24 lakh. Allegro Capital and its director as well as major shareholder Kunal Ashok Kashyap have been fined Rs 10 lakh each, according to an order by Sebi dated July 8.
Profit up due to strong performance of biopharma segment.
Industry leaders, including Mahindra Group chairman Anand Mahindra, RPG Enterprises chairman Harsh Goenka and Biocon Ltd chairperson Kiran Mazumdar-Shaw on Monday came out in support of the Agnipath scheme, saying it has large potential for employment of youth in the corporate sector. Mahindra also expressed dismay over the violence against the scheme while asserting that the farm equipment to aerospace conglomerate welcomes the opportunity to recruit trained, capable and young people under the programme. The Agnipath scheme, announced on June 14, provides for the recruitment of youths between the age bracket of 17-and-half years to 21 for only four years with a provision to retain 25 per cent of them for 15 more years.
'The obvious opportunity is biosimilars, which are simpler but more expensive,' says Kiran Mazumdar-Shaw, founder of Biocon.
From steel tycoon Lakshmi Mittal to billionaire Sunil Bharti Mittal's Airtel, Anil Agarwal's Vedanta, ITC, Mahindra and Mahindra, and a lesser-known Future Gaming and Hotel Services were among the prominent buyers of the now-scrapped electoral bonds for making political donations.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances